Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
Status:
Recruiting
Trial end date:
2028-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, and tolerability of ASP0739, when
administered as a single agent and in combination with pembrolizumab.
This study will also evaluate the clinical response and other measures of anticancer activity
of ASP0739 when administered as a single agent and in combination with pembrolizumab based on
central and local assessment.